261 results about "Blood glucose monitoring" patented technology

Systems and methods for continuous measurement of an analyte in a host are provided. The system generally includes a continuous analyte sensor configured to continuously measure a concentration of analyte in a host and a sensor electronics module physically connected to the continuous analyte sensor during sensor use, wherein the sensor electronics module is further configured to directly wirelessly communicate displayable sensor information to a plurality of different types of display devices.

A blood glucose monitoring system is disclosed which provides for inducing an active pulse in the blood volume of a patient. The induction of an active pulse results in a cyclic, and periodic change in the flow of blood through a fleshy medium under test. By actively inducing a change of the blood volume, modulation of the volume of blood can be obtained to provide a greater signal to noise ratio. This allows for the detection of constituents in blood at concentration levels below those previously detectable in a non-invasive system. Radiation which passes through the fleshy medium is detected by a detector which generates a signal indicative of the intensity of the detected radiation. Signal processing is performed on the electrical signal to isolate those optical characteristics of the electrical signal due to the optical characteristics of the blood.

A system and method for continuous non-invasive glucose monitoring is disclosed. According to one embodiment of the present invention, the method includes the steps of (1) contacting a remote device to an area of biological membrane having a permeability level, the remote device comprising a sensor and a transmitter; (2) extracting the at least one analyte through and out of the area of biological membrane and into the sensor; (3) generating an electrical signal representative of a level of the at least one analyte; (4) transmitting the electrical signal to a base device; (5) processing the electrical signal to determine the level of the at least one analyte; and (6) displaying the level of the at least one analyte in real time. The system includes a remote device that includes a sensor that generates an electrical signal representative of the concentration of the at least one analyte; and a transmitter that transmits the electrical signal. The system further includes a base device that includes a receiver that receives the electrical signal; a processor that processes the electrical signal; and a display that displays the processed signal in real time.

An apparatus and method are provided for determining a patient's carbohydrate to insulin ratio (CIR) and insulin sensitivity factor (ISF), and using these values, along with values for current blood glucose level and deviation from target blood glucose level, for determining insulin dose in view of carbohydrate intake during a particular time period. The apparatus and method employ algorithms that can be implemented in any of a personal computer, personal data assistant, hand held computing device, blood glucose monitor, infusion pump, medication delivery pen, meter, calculator, among other therapeutic, diagnostic or informational devices used for managing a patient's blood glucose levels.

Present invention is a system of blood glucose monitoring and intensive insulin therapy in a ICU for strict maintenance of normoglycemia which reduces intensive care and hospital mortality and morbidity of critically ill adult patients. The findings of present study also reveal factors determining insulin doses needed to maintain normoglycemia as well as the impact of insulin dose versus blood glucose level on the observed outcome benefits have been established. The invention provides a control system that adapts the flow of the insulin infusion based on insulin requirement calculated by blood glucose levels and clinical parameters such as history of diabetes, Body Mass Index, blood glucose level on admission, reason of ICU admission, time in the ICU, type and severity of illness, caloric intake, obesity, drugs affecting insulin sensitivity). This automated insulin monitoring systems significantly reduces the workload and human resource management problems for intensive insulin therapy in patients in the ICU.

The present invention is directed towards apparatuses and methods for the automated measurement of blood analytes and blood parameters for bedside monitoring of patient blood chemistry. Particularly, the current invention discloses a programmable system that can automatically draw blood samples at a suitable programmable time frequency (or at predetermined timing), can automatically analyze the drawn blood samples and immediately measure and display blood parameters such as glucose levels, hematocrit levels, hemoglobin blood oxygen saturation, blood gases, lactate or any other blood parameter.

Microvascular complications of diabetes mellitus are closely related to blood glucose levels and fluctuations. The Glycostator statistical package was created to allow patients and health care providers simple access to “glycemic indicators” which permit a “snapshot view” of the effectiveness of the patient's diabetes management program. Glycostator functions provide a simple way of enhancing the information already provided by home blood glucose monitoring devices. To this end, a set of new indices, including one called the Virtual A1c, are computed in a recursive fashion from blood glucose test results to provide a more meaningful day-to-day assessment of glycemic control. All indices can be made available at the meter user interface on request. The displayed indices allow patients to improve glycemic control by identifying problems with blood glucose control and lability that are less easily recognized in traditional blood glucose meter statistical packages. Virtual A1c emulates hemoglobin A1c continuously and provides better day-to-day assessment of long term glycemic control than does the traditional average blood glucose report. The method for computing each of these indices, including the Virtual A1c, allows for their implementation in commercial blood glucose monitors.

New methods and systems for noninvasive glucose monitoring and sensing with electromagnetic waves or ultrasound are disclosed. The methods are based on absolute or relative measurement of tissue dimensions (or changes in the dimensions) including, but not limited to: thickness, length, width, diameter, curvature, roughness as well as time of flight of ultrasound and optical pulses and optical thickness, which change with changing blood glucose concentrations. By measuring noninvasively absolute or relative changes in at least one dimension of at least one tissue or tissue layer or absolute or relative changes in time of flight of ultrasound or optical pulses, one can monitor blood glucose concentration noninvasively.

A blood glucose monitoring kit includes a case constructed in the form of a bi-fold wallet which comprises an upper flap and a lower flap that are connected together through a fold. The case includes an outer layer constructed out of a water resistant and soft fabric and an inner layer constructed out of a water resistant material, the outer and inner layers being sewn together about their peripheries. A layer of cushioned material is preferably disposed between the inner and outer layers to provide the case with a soft feel. Blood glucose monitoring electronics are preferably integrated directly into the upper flap of the case, the electronics including a printed circuit board (PCB), a test port mounted on the PCB and a display mounted on the PCB. Preferably, the upper flap is provided with an opening through which the test port is externally accessible. Additionally, the upper flap is provided with a window through which the display is externally visible. A pouch is secured onto the inner surface of the lower flap and is sized and shaped to retain a plurality of disposable test components.

A glucose monitoring kit for storing, carrying and using a blood glucose monitoring system, which includes a meter, a container for storing test strips and at least one sampler, is configured with case having two halves pivotal relative to one another, and a retention system. The retention system includes a plurality of clips arranged so that the first clip extends along the central region of the case between the two halves and second and third clips coupled to one of the halves. At least one of the first, second and third clips is made from hard polymeric material and configured to removably receive the meter so that the meter can be used by the operator of the monitoring system while being retained in the at least one clip

New optical coherence tomography (OCT) techniques are disclosed which are designed to improve OCT glucose concentration measure accuracy and are capable of being performed on a continuous basis. New multi-wavelength optical coherence tomography (OCT) techniques are also disclosed and designed to reduce artifacts do to water. New optical coherence tomography (OCT) techniques are also disclosed for determining local profusion rates, local analyte transport rates and tissue analyte transport rates as a measure of tissue health, disease progression and state and tissue transplantation effectiveness.

In a method of recalibrating continuous glucose monitoring data from a user, operable on a digital processor, an indication from the user that the user has taken a meal is received (806). A self-monitored of blood glucose levels from the user (810) at two separate times during a day corresponding to when the user has taken a meal. A glucose signal is received from a continuous glucose monitoring sensor (818) at times corresponding to the two separate times that the user has taken a meal. Two reconstructed blood glucose values based on the glucose signal from the continuous monitoring sensor at times when the at least two self-monitored of blood glucose levels are received from the user. A linear regression is performed (822) using y=ax+b, wherein x corresponds to the two reconstructed blood glucose values and y corresponds to the two self-monitored of blood glucose levels thereby generating an estimation of a and b. A recalibration signal, including the estimation of a and b, is transmitted to the continuous glucose monitoring sensor (824) based on the linear regression.

A system and method is described that enables a health care provider to monitor and manage a health condition of a patient. The system includes a health care provider apparatus operated by a health care provider and a remotely programmable patient apparatus that is operated by a patient. The health care provider develops a script program using the health care provider apparatus and then sends the script program to a remotely programmable patient apparatus through a communication network such as the World Wide Web. The script program is a computer-executable patient protocol that provides information to the patient about the patient's health condition and that interactively monitors the patient health condition by asking the patient questions and by receiving answers to those questions. The answers to these health related questions are then forwarded as patient data from the remotely programmable patient apparatus to the health care provider apparatus through the communication network. The patient data may also include information supplied by a physiological monitoring device such as a blood glucose monitor that is connected to the remotely programmable patient apparatus. When the patient data arrives at the health care provider apparatus, the patient data is processed for further management of the patient's health condition by the health care provider, such as forwarding another script program to the remotely programmable patient apparatus.

A method for noninvasive blood glucose monitoring involves metabolic heat measurement and algorithm to correct interferences from environmental factors, and physiological or pathological conditions of subjects.

A portable insulin injection pen and blood glucose monitoring device is integrated into a single unit for testing and treating diabetes symptoms. The device has a housing of a size suitable for transport in a user's clothing pocket or handbag. Within the housing is a blood glucose monitoring system for receiving a sample of the user's blood and detecting its glucose level, an insulin injection mechanism for administering an insulin injection, and a microprocessor that calculates an insulin dosage appropriate to the detected blood glucose level and sets the insulin injection mechanism to administer the calculated insulin dosage. A communication device automatically informs a remote emergency service provider, such as 911 or an emergency service to which the user has subscribed, if the microprocessor determines that the detected blood glucose level presents a potential danger to the user. The microprocessor also calculates treatment regimens specific to a particular user based on the detected blood glucose level and displays the treatment regimens on an LCD display. In a particularly advantageous embodiment, a GPS receiver within the housing detects the location of the device, and the communication device, which can be a cellular telephone separate from the housing connected wirelessly to the unit via a Bluetooth connection or cellular telephone circuitry within the housing itself, transmits information regarding the location to the remote emergency service.

A system for predicting blood glucose values in a patient includes a remote wireless non-invasive spectral device, the remote wireless non-invasive spectral device generating a spectral scan of a body part of the patient. Also included are a remote invasive device and a central processing device. The remote invasive device generates a constituent value for the patient, while the central processing device predicts a blood glucose value for the patient based upon the spectral scan and the constituent value.

An insulin delivery supervisor (IDS) with a safety analysis and supervision function that can reside between the insulin request and the insulin delivery and can intercept any excessive insulin requests before the insulin was delivered. The IDS can be implemented in any system based on insulin pump or pen and will work with either SMBG or CGM modes of blood glucose monitoring.

The present invention relates to a method for estimating blood glucose levels using a noninvasive optical coherence tomography- (OCT-) based blood glucose monitor. An algorithm correlates OCT-based estimated blood glucose data with actual blood glucose data determined by invasive methods. OCT-based data is fit to the obtained blood glucose measurements to achieve the best correlation. Once the algorithm has generated sets of estimated blood glucose levels, it may refine the number of sets by applying one or more mathematical filters. The OCT-based blood glucose monitor is calibrated using an Intensity Difference plot or the Pearson Product Moment Correlation method.

Arrangements are provided including a fluid transport tube, or a needle, having a first end and a second end opposite the first end, and a lumen having an inner diameter. At least one fluid transport enhancing projection is disposed in the lumen and extends from the second end toward the first end. A discreet, wearable blood glucose monitor including such arrangements is also described.

A system for predicting hypoglycemia based on continuous blood glucose monitor values is provided. The hypoglycemia detection algorithm is a set of individual alarms that are combined through a voting system into one combined alarm. The system could have five components and an overall voting algorithm that produces a binary alarm outcome depending on the number of constituent algorithms that report an alarm. A controller system automatically shuts off the insulin pump when pending or real hypoglycemia has been reached. The algorithms operate in a closed loop and automatically take action when the subject is asleep.